DeepMed Research

Danazol

Generic Name: Danazol

Brand Names: Cyclomen

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₇NO_₂

CAS Number: 17230-88-5

Unique Ingredient Identifier: N29QWW3BUO

Background: A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.

Indication: For the treatment of endometriosis and fibrocystic breast disease (in patients unresponsive to simple measures). Also used for the prophylactic treatment of all types of hereditary angioedema in males and females.

Associated Conditions: Endometriosis, Fibrocystic Disease of Breast, Hereditary Angioedema (HAE), Refractory immune thrombocytopenia

Clinical Trials

Efficacy and Safety Study to Evaluate Two Doses of Oral DMI-5207 in Adult Subjects With Diabetic Macular Edema

Phase 2

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: Danazol

First Posted Date: 2013-12-05

Last Posted Date: 2013-12-06

Lead Sponsor: Unity Health Toronto

Target Recruit Count: 34

Registration Number: NCT02002403

A Safety and Efficacy Study of Oral Danazol (a Previously Approved Drug) in the Treatment of Diabetic Macular Edema.

Phase 2

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: Danazol Capsules
Drug: Placebo

First Posted Date: 2013-04-01

Last Posted Date: 2022-10-10

Lead Sponsor: Ampio Pharmaceuticals. Inc.

Target Recruit Count: 354

Registration Number: NCT01821677

Danazol Treatment in Endometriosis Women Before IVF

Phase 4

Completed

Conditions: Ovarian Cysts
Infertility
Endometriosis

Interventions: Drug: placebo
Drug: Danazol

First Posted Date: 2013-01-30

Last Posted Date: 2016-04-27

Lead Sponsor: Centre for Endocrinology and Reproductive Medicine, Italy

Target Recruit Count: 150

Registration Number: NCT01779232

Locations: 🇮🇹
CERM, Rome, Italy

Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis

Phase 2

Completed

Conditions: Anemia
Primary Myelofibrosis
Secondary Myelofibrosis

Interventions: Drug: ruxolitinib phosphate
Drug: danazol
Other: quality-of-life assessment
Other: questionnaire administration

First Posted Date: 2012-11-22

Last Posted Date: 2017-10-18

Lead Sponsor: Mayo Clinic

Target Recruit Count: 14

Registration Number: NCT01732445

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Tisch Cancer Center, New York, New York, United States

The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia

Phase 2

Completed

Conditions: Autoimmune Thrombocytopenia

Interventions: Drug: All-trans retinoic acid
Drug: Danazol

First Posted Date: 2012-08-17

Last Posted Date: 2017-09-07

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 130

Registration Number: NCT01667263

Locations: 🇨🇳
Beijing Hospital, Ministry of Health, Beijing, Beijing, China
🇨🇳
Beijing Tongren Hospital, Beijing, Beijing, China
🇨🇳
Peking University People's Hospital, Peking University Insititute of Hematology, Beijing, Beijing, China

and more 2 locations

Danazol for Genetic Bone Marrow and Lung Disorders

Phase 1

Completed

Conditions: Aplastic Anemia

Interventions: Drug: Danazol

First Posted Date: 2011-09-27

Last Posted Date: 2018-08-15

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 27

Registration Number: NCT01441037

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

An Open-Label, MultiCenter Evaluation of the Use of Topically Administered FP1198 in Subjects With Pain Associated With Cyclic Mastalgia

Phase 2

Completed

Conditions: Moderate to Severe Cyclic Mastalgia

First Posted Date: 2010-04-16

Last Posted Date: 2011-10-26

Lead Sponsor: FemmePharma Global Healthcare, Inc.

Target Recruit Count: 20

Registration Number: NCT01105793

Locations: 🇺🇸
Women's Health Care, San Diego, California, United States
🇺🇸
Horizons Clinical Research, Denver, Colorado, United States
🇺🇸
Kentucky Medical Research Center, Lexington, Kentucky, United States

and more 1 locations

Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita

Phase 1

Terminated

Conditions: Fanconi Anemia
Dyskeratosis Congenita

Interventions: Drug: danazol

First Posted Date: 2009-10-26

Last Posted Date: 2019-02-19

Lead Sponsor: Boston Children's Hospital

Target Recruit Count: 5

Registration Number: NCT01001598

Locations: 🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States

Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)

Phase 2

Terminated

Conditions: Thrombotic Thrombocytopenic Purpura

Interventions: Drug: Danazol

First Posted Date: 2009-08-06

Last Posted Date: 2024-07-23

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 9

Registration Number: NCT00953771

Locations: 🇺🇸
Mount Sinai St. Luke's-Roosevelt, New York, New York, United States

Pain Associated With Endometriosis

Phase 2

Completed

Conditions: Endometriosis

Interventions: Drug: Danazol Once Weekly
Drug: Danazol Twice Weekly
Drug: Placebo Once Weekly
Drug: Placebo Twice Weekly

First Posted Date: 2008-09-25

Last Posted Date: 2012-03-06

Lead Sponsor: Lumara Health, Inc.

Target Recruit Count: 66

Registration Number: NCT00758953

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy